Testicular dose and fertility in men following I(131) therapy for thyroid cancer
- PMID: 12072044
- DOI: 10.1046/j.1365-2265.2002.t01-1-01545.x
Testicular dose and fertility in men following I(131) therapy for thyroid cancer
Abstract
Objective: Young adults with differentiated thyroid cancer are treated with high doses of radioiodine and have an excellent long-term prognosis. However, there is limited information on the effects of this treatment on the gonads and fertility in male patients. We have reviewed the outcome of treatment in our centre with respect to male fertility. We have also assessed directly the radiation dose received by the testes.
Design: Retrospective analysis of males attending the thyroid clinic at the Royal Marsden Hospital for treatment of differentiated thyroid cancer. A prospective study was also performed to assess radiation dose to testes in 14 consecutive patients attending for thyroid cancer treatment.
Patients: Males under the age of 40 years at the time of treatment with a minimum of 3 years follow-up.
Measurements: Number of children fathered by patients and number of congenital malformations. For the prospective study: gonadal function assessed by serum FSH, LH and testosterone measurements; radiation dose to the testes (Gy) measured by thermoluminescent dosimetry.
Results: Fertility was assessed in 122 men with a median follow-up of 21 years (range 3-39) of whom 93 were under active follow-up. One hundred and six children were fathered by 59 patients; the remainder had no wish to have children. No major malformations were reported. Of these 59 patients, 12 had received a single 3 GBq ablation dose, 19 had been treated with up to 14 GBq radioiodine and 28 had received up to 44 GBq. In 14 patients followed prospectively, the median estimated radiation dose to each testis was 6.4 cGy following 3 GBq, 14.1 cGy following 5.5 GBq and 21.2 cGy following 9.2 GBq. There was a transient elevation in serum FSH after radioiodine which normalized within 9 months from the last administration.
Conclusions: Radioiodine treatment for thyroid cancer may result in transient impairment of gonadal function. The radiation dose absorbed by the testis after a single ablative dose of radioiodine is well below that associated with permanent damage to germinal epithelium and the risk of infertility in these patients is minimal. Patients requiring multiple administrations for persistent or metastatic thyroid cancer may be at greater risk of gonadal damage although even in this group, we found no evidence of infertility.
Comment in
-
Gonadal damage from 131I therapy for thyroid cancer.Clin Endocrinol (Oxf). 2002 Sep;57(3):313-4. doi: 10.1046/j.1365-2265.2002.01611.x. Clin Endocrinol (Oxf). 2002. PMID: 12201822 No abstract available.
Similar articles
-
Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer.Postgrad Med J. 2002 Feb;78(916):92-3. doi: 10.1136/pmj.78.916.92. Postgrad Med J. 2002. PMID: 11807191 Free PMC article. Review.
-
Testicular function after radioiodine therapy for thyroid carcinoma.Eur J Nucl Med. 2000 May;27(5):503-7. doi: 10.1007/s002590050535. Eur J Nucl Med. 2000. PMID: 10853804 Clinical Trial.
-
Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.J Nucl Med. 1999 Oct;40(10):1716-21. J Nucl Med. 1999. PMID: 10520714 Clinical Trial.
-
Gonadal effect of radiation from 131I in male patients with thyroid carcinoma.Arch Androl. 2005 May-Jun;51(3):171-5. doi: 10.1080/014850190898746. Arch Androl. 2005. PMID: 16025855 Review.
-
Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine.J Nucl Med. 1994 Sep;35(9):1418-22. J Nucl Med. 1994. PMID: 8071685
Cited by
-
Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach.Pediatr Radiol. 2019 Oct;49(11):1391-1403. doi: 10.1007/s00247-019-04457-7. Epub 2019 Oct 16. Pediatr Radiol. 2019. PMID: 31620841 Review.
-
Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.Endocrine. 2015 Sep;50(1):61-6. doi: 10.1007/s12020-015-0668-9. Epub 2015 Jun 25. Endocrine. 2015. PMID: 26109472 Review.
-
Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.Nucl Med Mol Imaging. 2018 Aug;52(4):247-253. doi: 10.1007/s13139-018-0522-0. Epub 2018 May 2. Nucl Med Mol Imaging. 2018. PMID: 30100937 Free PMC article. Review.
-
Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II.Nucl Med Mol Imaging. 2025 Feb;59(1):8-26. doi: 10.1007/s13139-024-00886-x. Epub 2024 Nov 1. Nucl Med Mol Imaging. 2025. PMID: 39881975 Review.
-
Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer.Basic Clin Androl. 2015 Aug 2;25:8. doi: 10.1186/s12610-015-0024-1. eCollection 2015. Basic Clin Androl. 2015. PMID: 26236480 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical